Skip to main content

Cristina Hernández Pascual

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Cristina Hernández Pascual

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Pendent

IP: Cristina Hernández Pascual
Collaborators: Miriam Izquierdo Sans, Efráin Santiago Cordero Vázquez
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: INT21/00092
Duration: 01/01/2022 - 31/12/2022

Estudio de seguridad y eficacia de la sitagliptina en colirio para el tratamiento de los estadios iniciales de retinopatía diabética.

IP: Rafael Simó Canonge
Collaborators: Marc Rivas Agudo, Cristina Hernández Pascual, José García Arumí
Funding agency: Instituto de Salud Carlos III
Funding: 573650
Reference: ICI20/00129
Duration: 01/01/2021 - 31/10/2026

H2O Health Outcomes Observatory

IP: Yolima Cossio Gil
Collaborators: Cristina Hernández Pascual, Natalia Borruel Sainz, Gemma Galán Martinez, Monica Sanchez Bartres, Marta Ferri Peradalta, Rafael Simó Canonge, Joan Carles Peiró Ruiz
Funding agency: The Innovative Medicines Initiative
Funding: 1097257.5
Reference: H2O_IMI2-2020
Duration: 01/10/2020 - 30/09/2025

Administración tópica ocular de inhibidores de DPP-4: una nueva estrategia terapéutica para la retinopatía diabética

IP: Cristina Hernández Pascual
Collaborators: Enzamaría Fidilio Meli, Miriam Izquierdo Sans
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 63589.78
Reference: 2020 FI_B 0046
Duration: 01/05/2020 - 29/04/2021

Related news

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Related professionals

Joaquim Vives Armengol

Joaquim Vives Armengol

Main researcher
Musculoskeletal Tissue Engineering
Read more
Nuria Casalé Cabanes

Nuria Casalé Cabanes

Predoctoral researcher
Infectious Diseases
Read more
Marcos Buj Vicente

Marcos Buj Vicente

Junior researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Jaume Alijotas Reig

Jaume Alijotas Reig

Head of group
Systemic Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.